Progress in the evaluation of modified vaccinia Ankara vaccine against mpox

被引：2
|
作者：
Mazzotta, Valentina [1 ]
Matusali, Giulia [2 ]
Oliva, Alessandra [1 ]
Maggi, Fabrizio [2 ]
Antinori, Andrea [1 ]
机构：
[1] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Clin & Res Infect Dis Dept, I-00149 Rome, Italy
[2] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Lab Virol, I-00149 Rome, Italy
来源：
LANCET INFECTIOUS DISEASES | 2023年 / 23卷 / 11期
关键词：
D O I：
10.1016/S1473-3099(23)00369-9
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：1214 / 1215
页数：2
相关论文
共 50 条
  • [21] Decline of Mpox Antibody Responses After Modified Vaccinia Ankara-Bavarian Nordic Vaccination
    Collier, Ai-ris Y.
    McMahan, Katherine
    Jacob-Dolan, Catherine
    Liu, Jinyan
    Borducchi, Erica N.
    Moss, Bernard
    Barouch, Dan H.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (19): : 1669 - 1672
  • [22] IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection
    Jones, Taff
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (04) : 407 - 417
  • [23] Modified vaccinia virus Ankara as vaccine vectors in human and veterinary medicine
    Quinan, Barbara R.
    Daian, Danielle S. O.
    Coelho, Fabiana M.
    da Fonseca, Flavio G.
    FUTURE VIROLOGY, 2014, 9 (02) : 173 - 187
  • [24] Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses
    Kreijtz, J. H. C. M.
    Suezer, Y.
    de Mutsert, G.
    van den Brand, J. M. A.
    van Amerongen, G.
    Schnierle, B. S.
    Kuiken, T.
    Fouchier, R. A. M.
    Loewer, J.
    Osterhaus, A. D. M. E.
    Sutter, G.
    Rimmelzwaan, G. F.
    VACCINE, 2009, 27 (45) : 6296 - 6299
  • [25] Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox
    Deng, Lucy
    Lopez, Laura K.
    Glover, Catherine
    Cashman, Patrick
    Reynolds, Renee
    Macartney, Kristine
    Wood, Nicholas
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (23): : 2091 - 2094
  • [26] Clinical characteristics of mpox infection in individuals who received a first dose of modified vaccinia Ankara immunisation
    Agunbiade, Simisola
    Burton, Felicity
    Muirhead, Jessica
    Whitlock, Gary George
    Girometti, Nicolo
    SEXUALLY TRANSMITTED INFECTIONS, 2023, 99 (03) : 198 - 199
  • [27] Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART
    Cosma, Antonio
    Nagaraj, Rashmi
    Staib, Caroline
    Diemer, Claudia
    Wopfner, Franziska
    Schatzl, Hermann
    Busch, Dirk H.
    Sutter, Gerd
    Goebel, Frank D.
    Erfle, Volker
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (06) : 782 - 793
  • [28] Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice
    Brewoo, Joseph N.
    Powell, Tim D.
    Stinchcomb, Dan T.
    Osorio, Jorge E.
    VACCINE, 2010, 28 (36) : 5891 - 5899
  • [29] Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine
    Phelps, A. L.
    Gates, A. J.
    Hillier, A.
    Eastaugh, L.
    Ulaeto, D. O.
    VACCINE, 2007, 25 (01) : 34 - 42
  • [30] Heat-inactivated modified vaccinia virus Ankara (MVA) as vaccine adjuvant
    Yang, Ning
    Shuman, Stewart
    Merghoub, Taha
    Wolchok, Jedd
    Deng, Liang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345